MARKET

SAGE

SAGE

Sage Therapeutic
NASDAQ
37.92
+0.13
+0.34%
After Hours: 37.92 0 0.00% 16:02 11/28 EST
OPEN
37.53
PREV CLOSE
37.79
HIGH
38.81
LOW
37.53
VOLUME
630.46K
TURNOVER
0
52 WEEK HIGH
45.74
52 WEEK LOW
27.36
MARKET CAP
2.26B
P/E (TTM)
-4.3959
1D
5D
1M
3M
1Y
5Y
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass., November 23, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34th Annual Healthcare C...
Business Wire · 5d ago
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
CAMBRIDGE, Mass., November 22, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their inv...
Business Wire · 6d ago
Insider Buy: Sage Therapeutics
Insider Buy: Sage Therapeutics
MT Newswires · 11/15 16:17
Guggenheim Maintains Buy on Sage Therapeutics, Lowers Price Target to $48
Benzinga · 11/11 13:55
--Guggenheim Adjusts Price Target on Sage Therapeutics to $48 From $55, Maintains Buy Rating
--Guggenheim Adjusts Price Target on Sage Therapeutics to $48 From $55, Maintains Buy Rating
MT Newswires · 11/11 09:28
BMO Capital Maintains Market Perform on Sage Therapeutics, Lowers Price Target to $40
Benzinga · 11/09 14:52
--BMO Capital Adjusts Price Target on Sage Therapeutics to $40 From $43, Maintains Market Perform Rating
--BMO Capital Adjusts Price Target on Sage Therapeutics to $40 From $43, Maintains Market Perform Rating
MT Newswires · 11/09 12:08
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
CAMBRIDGE, Mass., November 09, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on W...
Business Wire · 11/09 11:30
More
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. It targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. It has a portfolio of other compounds that target GABAA receptors, including SAGE-324.

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.